Cocrystal Pharma, Inc., a biotechnology company, has announced the closing of a registered direct offering, generating up to $13 million in gross proceeds. The offering includes the sale of 2,764,710 shares of common stock priced at $1.70 per share, raising $4.7 million upfront. Additionally, unregistered warrants have been issued through a concurrent private placement, allowing the purchase of up to 5,529,420 shares of common stock at an exercise price of $1.50 per share. These warrants are exercisable immediately and will expire 24 months from the effective date of the registration statement. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-013495), on September 15, 2025, and is solely responsible for the information contained therein.